Your browser doesn't support javascript.
loading
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
Bonaventura, Jordi; Lam, Sherry; Carlton, Meghan; Boehm, Matthew A; Gomez, Juan L; Solís, Oscar; Sánchez-Soto, Marta; Morris, Patrick J; Fredriksson, Ida; Thomas, Craig J; Sibley, David R; Shaham, Yavin; Zarate, Carlos A; Michaelides, Michael.
Afiliación
  • Bonaventura J; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. jordi.bonaventura@nih.gov.
  • Lam S; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Carlton M; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Boehm MA; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Gomez JL; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Solís O; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Sánchez-Soto M; Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, MD, USA.
  • Morris PJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, USA.
  • Fredriksson I; Neurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Thomas CJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, USA.
  • Sibley DR; Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, MD, USA.
  • Shaham Y; Neurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
  • Zarate CA; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Intramural Research Program, Bethesda, MD, USA.
  • Michaelides M; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. mike.michaelides@nih.gov.
Mol Psychiatry ; 26(11): 6704-6722, 2021 11.
Article en En | MEDLINE | ID: mdl-33859356
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Resistente al Tratamiento / Ketamina Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Resistente al Tratamiento / Ketamina Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos